Direct binding of Grb2 has an important role in the development of myeloproliferative disease induced by ETV6/FLT3
Leukemia (2013) 27, 1433-1436; doi:10.1038/leu.2012.333 FMS-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in hematological malignancies. 1 The most common mutations of FLT3 are internal tandem duplications (ITDs) within the juxtamembrane domain, which occur in 20% to 30% of patients with acute myeloid leukemia (AML). 2, 3 Although FLT3 is a potential therapeutic target in AML, recent studies involving FLT3 inhibitors as single agents in patients with AML showed limited clinical responses. 4 FLT3 has been reported to fuse to ETV6 (TEL) in a few cases of myeloid/lymphoid neoplasms with eosinophilia (MLN-eo) carrying a translocation t(12;13)(p13;q12). 5, 6 Although it has been shown that ETV6/FLT3 acts as a constitutively active tyrosine kinase, the molecular mechanisms underlying ETV6/FLT3-mediated leukemogenesis remain incompletely understood. [7] [8] [9] We identified a novel ETV6/FLT3 variant fusion transcript (E/F-1) in a MLN-eo patient (Supplementary Figures S1A and B) and investigated the transforming properties of ETV6/FLT3 in vivo using a murine bone marrow transplant (BMT) model. 10 ,11 E/F-1-transduced recipients developed an aggressive polyclonal myeloproliferative disease (MPD) in 100% of recipient mice with a latency of 3-4 weeks, as evidenced by marked leukocytosis, splenomegaly and massive expansion of myeloid cells in peripheral blood, spleen and bone marrow ( Figures 1A-C) . In this mice model, eosinophilia was not observed. Flow cytometric analysis of the peripheral blood from E/F-1 mice showed a large population of EGFP
In primary E/F-1 mice, serial passage was performed by transferring a 1:1 mixture of spleen and bone marrow cells to sublethally irradiated recipient mice. This resulted in hematopoietic malignancies in most of the recipient mice receiving five different primary tumors. For three of the primary tumors, it was possible to transmit the MPD for at least one round. In all cases of serial passage, the MPD transformed into aggressive T-lymphoblastic lymphoma (T-LBL) with a latency of 4-17 weeks ( Figure 1E , Supplementary Figure  S2B ). Most lymphoma occurred in the thymus or abdominal lymph nodes, and some of the secondary recipient mice displayed leukocytosis, generalized lymphadenopathy or hepatosplenomegaly. Histopathological examination revealed that the architecture of the lymph nodes and the thymus was completely effaced and that they contained a uniform population of lymphoblasts. The liver showed prominent periportal, lobular and sinusoidal Accepted article preview online 20 November 2012; advance online publication, 14 December 2012 Letters to the Editor infiltration by lymphoma cells ( Figure 1D ). Flow cytometric analysis of spleen cells revealed that the lymphomas typically showed an immature T-cell immunophenotype characterized by expression of both CD4 and CD8 (Supplementary Figure S2A) . Affected tissues from secondary diseased mice contained proviral integrations identical to those in the primary MPD mouse ( Figure 1F ). ETV6/FLT3-induced T-LBL was transplantable, with all tertiary transplant recipients rapidly succumbing to T-LBL at 4-7 weeks after transfer arising from common clones identified in the secondary mice (Supplementary Figure S2C) .
Previous studies have shown that FLT3-ITDs induce a lethal MPD in mice and that tyrosine residues 589 and 591 in the juxtamembrane domain of FLT3 are critical for STAT5 phosphorylation and generation of the MPD phenotype. 10 We also demonstrated the corresponding results for FLT3-ITD in our murine BMT experiment ( Supplementary Figures S3A and B) . On the other hand, mice that received the double tyrosineto-phenylalanine mutant of E/F-1 at sites 589 and 591 (Y589/591F) in the juxtamembrane domain of FLT3 developed a similar MPD (Supplementary Table S1 ). There was no significant difference in survival between recipients of E/F-1 vs Y589/591F, with both mice groups succumbing to a fatal MPD within a median survival time of 18 and 19.5 days, respectively (P ¼ 0.284; Figure 1C ). The Y589/ 591F mutation did not abrogate STAT5, Erk1/2 and Akt activation in Ba/F3 cells transformed by E/F-1 (Supplementary Figure S4) , which is consistent with the previous studies using a deletion mutant of the FLT3 juxtamembrane domain in ETV6/FLT3. 9 Growth factor receptor-binding protein 2 (Grb2) is an adaptor protein known to bind several receptor tyrosine kinases. Grb2 binds the scaffolding protein Grb2-associated binder 2 (Gab2) and contributes to survival signaling in ligand-activated wild-type FLT3. 12 A recent study has shown that tyrosines 768, 955 and 969 of FLT3 are the direct Grb2-binding sites of importance for FLT3-ITD-mediated proliferation and survival of hematopoietic cells in vitro as a result of STAT5 activation via Gab2. 13 However, there have been no reports regarding the in vivo effects of direct Grb2 binding by oncogenic FLT3 in leukemogenesis. Thus, we investigated the role of Grb2 binding in ETV6/FLT3-mediated leukemogenesis. Inspection of the ETV6 portion of the fusion protein revealed only two candidate tyrosines for direct binding of Grb2 at positions 314 and 354. To test whether Grb2 binds directly to ETV6/FLT3, we made a series of Grb2-binding mutants of ETV6/ FLT3 (Figure 2a) . The Y314/354F double point mutant (2F) and the Y768/955/969F triple mutant (3F-1) of E/F-1 showed a reduced ability to bind Grb2 as compared with the E/F-1. Furthermore, when we mutated tyrosines 314 or 354 to phenylalanine in the context of the Y768/955/969F triple mutant, the association of ETV6/FLT3 with Grb2 was significantly reduced as compared with the Y768/955/969F triple mutant. Finally, when we mutated all five specific tyrosines (Y314/354/768/955/969) to phenylalanine, we observed that ETV6/FLT3 was no longer able to bind Grb2 (Figure 2b ). Simultaneous mutation of these five tyrosine residues resulted in an absence of Gab2 phosphorylation, and impaired activation of STAT5, Erk1/2 and Akt in Ba/F3 cells (Figure 2c ). ETV6/ FLT3 variant E/F-2, which lacked the Grb2-binding sites of ETV6, was unable to bind to Grb2 when all three Grb2-binding sites of (d) Cytokine-independent colony formation of whole bone marrow cells expressing ETV6/FLT3 wild-type or Grb2-binding mutants. The difference between E/F-1 and 5F (*) and between E/F-2 and 3F-2 (**) is statistically significant (Po0.001, unpaired t-test). Data are the mean ± s.d. of three independent experiments. (e) Survival curve for recipients of bone marrow transduced with ETV6/FLT3 and Grb2-binding mutants. Both E/F-1 and E/F-2 mice caused rapidly fatal MPD. 5F mutant mice and 3F-2 mutant mice developed MPD with a longer median survival of 55 and 73 days, respectively (Po0.001 vs E/F-1 and E/F-2, respectively). One of the 5F mutant mice died of severe anemia without showing any signs of MPD. Survival data are cumulative from two or three separate experiments for all retroviral constructs. (f ) Survival curve for recipients of Gab2 À / À and Gab2 þ / þ bone marrow transduced with a vector control or E/F-1. The P-value represents a comparison of survival by E/F-1 on Gab2
FLT3 were mutated (Figure 2b ). This Y768/955/969F triple mutant of E/F-2 (3F-2) was also unable to phosphorylate Gab2 and showed weaker activation of STAT5, Erk1/2 and Akt as compared with E/F-2 in Ba/F3 cells (Figure 2c) . Both E/F-1 and E/F-2 transformed bone marrow cells to be capable of cytokineindependent growth in methylcellulose medium. Transformation was significantly decreased in the 5F and 3F-2 mutants, which were unable to bind Grb2, but not in 2F and 3F-1 mutants (Figure 2d ). To examine the contribution of Grb2 binding to ETV6/ FLT3-induced MPD in vivo, we performed BMT experiments. White blood cell (WBC) counts and spleen weights of the mice receiving 5F-transduced bone marrow were significantly lower than those receiving E/F-1-transduced bone marrow (Supplementary  Table S1 ). Flow cytometric analyses of spleen cells showed that 5F mice had a reduced fraction of Mac-1 þ /Gr-1 þ cells compared with E/F-1 mice (Supplementary Figure S5A) . 5F mice showed significantly less infiltrate in the hepatic lobules or periportal areas than the E/F-1 mice (Supplementary Figure S5B) . Recipients of both 2F and 3F-1 developed rapidly fatal MPD with a comparable latency to those of E/F-1. Survival of 5F and 3F-2 mice was significantly prolonged compared with that of E/F-1 and E/F-2 mice, respectively (55 days vs 18 days, 73 days vs 13 days, respectively; Po0.001; Figure 2e ), although most 5F and 3F-2 recipient mice eventually succumbed to MPD.
Finally, we compared the ability of ETV6/FLT3 to transform primary myeloid cells from the bone marrow of Gab2 À / À and Gab2 þ / þ mice. Expression of E/F-1 in Gab2 À / À cells resulted in an approximately threefold lower number of cytokine-independent CFU-C (Supplementary Figure S6A) . We assessed the relative contribution of the Gab2 gene to ETV6/FLT3-mediated leukemogenesis in BMT experiments using Gab2 À / À and Gab2 þ / þ donor mice. All mice transplanted with Gab2 Our results suggest that ETV6/FLT3 has more potent oncogenic activity than FLT3-ITDs and can transform progenitor cells with the capacity to differentiate into myeloid and lymphoid progeny, supporting the contention that human ETV6/FLT3-positive MLN-eo is a stem cell disorder. Unlike FLT3-ITDs, mice that received the Y589/591F mutant of ETV6/FLT3 also developed a lethal MPD with a short latency. The reason for the discrepancy between ETV6/ FLT3 and FLT3-ITDs is not clear. This may be due to altered structural conformation of ETV6/FLT3 relative to wild-type FLT3 or alternatively, it may be due to different subcellular localization of the fusion protein and FLT3-ITDs. 14, 15 Recently it was reported that sunitinib and sorafenib, tyrosine kinase inhibitors with multiple targets including FLT3, had therapeutic efficacy in two patients with ETV6/FLT3-positive MLN-eo. 6 Unfortunately, similar to most of the patients with FLT3-ITD-positive AML, relapse and resistance occurred in both patients. Although clinical application of Grb2 inhibitors remains limited to just a phase I trial of a liposomal antisense for hematological malignancies, the results of the current study indicate therapeutic potential against Grb2 in patients with ETV6/FLT3-positive MLN-eo. In addition, previous studies have shown that the Grb2-Gab2 pathway also has an important role in FLT3-ITD-mediated cell proliferation and survival. 13, 15 These findings suggest that inhibition of this pathway may be useful in the treatment of FLT3-associated leukemia.
